Eikon announced itself in 2021 with former Merck & Co. exec Roger Perlmutter, M.D., Ph.D., at the helm and quickly ...
Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with standard-of-care ...
Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to ...
Sustained interest in small molecules, bispecific antibodies, and genomics got the ball rolling in the biotech deals arena in ...
Investigational antiviral pritelivir demonstrates efficacy and improved tolerability over current treatments for refractory HSV in high-risk patients.
Clinical Trials Arena on MSN
AiCuris reports positive Phase III pritelivir results for HSV patients
The trial enrolled and treated 101 immunocompromised patients with refractory or resistant HSV infection.
AZoLifeSciences on MSN
New research reveals RFC's dynamic partnership in DNA synthesis
Every time a cell divides, it must copy its entire genome so that each daughter cell inherits a complete set of DNA. During that process, enzymes known as polymerases race along the DNA to copy its ...
The offering is one of four biotech IPOs that could price by Friday, and comes during the busiest week for such activity since early last year.
Kinoteck Therapeutics Co. Ltd. has discovered nitrogen-containing heterocyclic derivatives acting as Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors potentially useful for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results